Epidemiological Study to Evaluate the Prevalence of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic NSCLC (Stage IIIB/IV Non-small Cell Lung Cancer)
N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Non Small Cell Lung Cancer
Both
Non Small Cell Lung Cancer
Trial Information
Epidemiological Study to Evaluate the Prevalence of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic NSCLC (Stage IIIB/IV Non-small Cell Lung Cancer)
Inclusion Criteria:
- Signed written informed consent
- Histologically confirmed locally advanced or metastatic NSCLC (stage IIIB/IV)
Exclusion Criteria:
- Mixed histology of small cell and non-small cell lung cancer
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Cross-Sectional
Outcome Measure:
To estimate the prevalence of EGFR mutation in a representative sample of patients with newly diagnosed stage IIIB/IV NSCLC in Spain (predominantly Caucasian ethnicity).
Safety Issue:
No
Principal Investigator
Carmen Gonzalez Arenas
Investigator Role:
Study Director
Investigator Affiliation:
Medical Department. Mediclin-AstraZeneca. Spain
Authority:
Spain: Ethics Committee
Study ID:
NIS-OES-DUM-2009/1
NCT ID:
NCT01081496
Start Date:
March 2010
Completion Date:
February 2011
Related Keywords:
- Non Small Cell Lung Cancer
- EGFR mutation, Non-small cell lung carcinoma, Spain
- Evaluate the prevalence of EGFR mutation status in patients with newly diagnosed locally advanced or metastatic NSCLC
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|
